Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Plerixafor for stem cell mobilization: the current status.

Current opinion in hematology - 1 Jan 2016

Bilgin Yavuz M, de Greef Georgine E

Abstract excerpt

PURPOSE OF REVIEW: Nowadays, plerixafor is approved for patients who fail to mobilize sufficient CD34⁺ cells for an autologous stem cell transplantation. Plerixafor is effective in the majority of these patients, who otherwise could not be treated adequately. We discussed in this review the current status of the optimal use of plerixafor in different clinical diagnoses and settings. RECENT FINDINGS: Plerixafor...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, CD34
Share to Benzylamines
Share to Cell Count

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cost-Benefit Analysis

Share to Hematopoietic Stem Cell Mobilization

Share to Heterocyclic Compounds

Share to Receptors, CXCR4

Share to Transplantation, Autologous

Source

Identifiers

PMID: 26554889
DOI: 10.1097/MOH.0000000000000200

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Plerixafor for stem cell mobilization: the current status.PMID 26554889Read ↗

Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major.Semantic proximity Read ↗

Effect of daratumumab on stem cell yields in patients with newly diagnosed multiple myeloma: a report from the Multiple Myeloma GroupSemantic proximity Read ↗

Predictive model of the efficiency of hematopoietic stem cell collection in patients with multiple myeloma and lymphoma based on multiple peripheral blood markersSemantic proximity Read ↗

Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersSemantic proximity Read ↗

Cytokines and hematopoietic stem cell mobilization.Semantic proximity Read ↗

Autologous transplantation with peripheral blood stem cells in chronic lymphocytic leukemia. A phase III, randomized, multicenter study. GIMEMA. Gruppo Italiano per le Malattie Ematologiche dell'Adulto. GITMO-Gruppo Italiano Trapianto di Midollo Osseo.Semantic proximity Read ↗

[Monitoring the mobilization of peripheral blood stem cells with G-CSF for allogenic transplantation].Semantic proximity Read ↗

Disease severity impacts plerixafor-mobilized stem cell collection in patients with sickle cell diseaseSemantic proximity Read ↗

A single-center historical control study of eltrombopag combined with immunosuppressive therapy for severe aplastic anemia in childrenSemantic proximity Read ↗

Eltrombopag for Treatment of Thrombocytopenia After Autologous Stem Cell Transplantation in Children: Single Center ExperienceSemantic proximity Read ↗

A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: results of a European phase II study.Semantic proximity Read ↗

Safe and efficient peripheral blood stem cell collection in patients with sickle cell disease using plerixaforSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.